Gene study reveals clues about ulcerative colitis risk and drug effectiveness
NCT ID NCT07564895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined how differences in the BAFF gene might affect a person's risk of developing ulcerative colitis and how well they respond to the drug vedolizumab. Researchers analyzed genetic samples from 841 people with ulcerative colitis. The goal was to better understand the disease and potentially improve treatment choices in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Can a new pill tame ulcerative colitis Flare-Ups?
- Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out
- Can a new pill tame ulcerative colitis when others fail?
- Can a pill tame ulcerative colitis? new trial seeks answers